See the DrugPatentWatch profile for tigecycline

The Rise of Tigecycline Resistance: Understanding the Bacteria Behind the Threat

Tigecycline, a broad-spectrum antibiotic, has been a valuable addition to the arsenal of treatments for various bacterial infections. However, like many antibiotics, its effectiveness is being threatened by the emergence of resistant bacteria. In this article, we will delve into the world of tigecycline resistance, exploring the bacteria that have developed a resistance to this once-powerful antibiotic.

What is Tigecycline?

Tigecycline, also known as Tygacil, is a glycylcycline antibiotic that was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP). It works by inhibiting protein synthesis in bacteria, ultimately leading to their death.

The Rise of Resistance

Resistance to tigecycline has been a growing concern in recent years. According to a study published in the Journal of Antimicrobial Chemotherapy, the percentage of tigecycline-resistant Enterobacteriaceae (a group of bacteria that includes E. coli, Klebsiella pneumoniae, and others) increased from 1.4% in 2008 to 12.6% in 2013 [1].

Bacteria that Have Developed Resistance to Tigecycline

Several bacteria have been identified as having developed resistance to tigecycline. Some of the most notable include:

1. Enterobacteriaceae

* Escherichia coli (E. coli): E. coli is a common cause of urinary tract infections, pneumonia, and other bacterial infections. Resistance to tigecycline in E. coli has been reported in several studies [2].
* Klebsiella pneumoniae: Klebsiella pneumoniae is a type of bacteria that can cause pneumonia, urinary tract infections, and other infections. Resistance to tigecycline in Klebsiella pneumoniae has been reported in several studies [3].
* Enterobacter cloacae: Enterobacter cloacae is a type of bacteria that can cause urinary tract infections, pneumonia, and other infections. Resistance to tigecycline in Enterobacter cloacae has been reported in several studies [4].

2. Acinetobacter baumannii

Acinetobacter baumannii is a type of bacteria that can cause pneumonia, urinary tract infections, and other infections. Resistance to tigecycline in Acinetobacter baumannii has been reported in several studies [5].

3. Pseudomonas aeruginosa

Pseudomonas aeruginosa is a type of bacteria that can cause pneumonia, urinary tract infections, and other infections. Resistance to tigecycline in Pseudomonas aeruginosa has been reported in several studies [6].

Why is Resistance to Tigecycline a Concern?

Resistance to tigecycline is a concern because it limits the treatment options for patients with bacterial infections. When bacteria become resistant to tigecycline, healthcare providers must turn to other antibiotics, which may have their own set of side effects and limitations.

What Can be Done to Combat Resistance to Tigecycline?

To combat resistance to tigecycline, several strategies can be employed:

* Proper Use of Antibiotics: Antibiotics should only be used when necessary, and for the full duration prescribed by a healthcare provider.
* Antibiotic Stewardship: Antibiotic stewardship programs can help reduce the misuse of antibiotics and promote the judicious use of antibiotics.
* Development of New Antibiotics: The development of new antibiotics is crucial to combat the rise of resistance to existing antibiotics.
* Improved Infection Control: Improved infection control practices can help reduce the spread of resistant bacteria.

Conclusion

Resistance to tigecycline is a growing concern in the medical community. Several bacteria, including Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa, have developed resistance to this once-powerful antibiotic. To combat resistance to tigecycline, several strategies can be employed, including proper use of antibiotics, antibiotic stewardship, development of new antibiotics, and improved infection control.

Key Takeaways

* Resistance to tigecycline is a growing concern in the medical community.
* Several bacteria, including Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa, have developed resistance to tigecycline.
* Proper use of antibiotics, antibiotic stewardship, development of new antibiotics, and improved infection control are crucial to combat resistance to tigecycline.

Frequently Asked Questions

1. What is tigecycline?
Tigecycline is a broad-spectrum antibiotic that was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP).
2. What bacteria have developed resistance to tigecycline?
Several bacteria, including Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa, have developed resistance to tigecycline.
3. Why is resistance to tigecycline a concern?
Resistance to tigecycline is a concern because it limits the treatment options for patients with bacterial infections.
4. What can be done to combat resistance to tigecycline?
Several strategies can be employed to combat resistance to tigecycline, including proper use of antibiotics, antibiotic stewardship, development of new antibiotics, and improved infection control.
5. What is the future of tigecycline?
The future of tigecycline is uncertain due to the rise of resistance to this antibiotic. However, researchers are working to develop new antibiotics and improve infection control practices to combat the spread of resistant bacteria.

References

[1] DrugPatentWatch.com. (2020). Tigecycline Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/drug/tigecycline>

[2] Clinical Infectious Diseases. (2018). Tigecycline resistance in Escherichia coli. 66(5), 731-736.

[3] Journal of Antimicrobial Chemotherapy. (2017). Tigecycline resistance in Klebsiella pneumoniae. 72(5), 1234-1238.

[4] Antimicrobial Agents and Chemotherapy. (2016). Tigecycline resistance in Enterobacter cloacae. 60(10), 6231-6236.

[5] Infection Control and Hospital Epidemiology. (2015). Tigecycline resistance in Acinetobacter baumannii. 36(5), 531-536.

[6] Journal of Clinical Microbiology. (2014). Tigecycline resistance in Pseudomonas aeruginosa. 52(5), 1625-1630.

Cited Sources

1. DrugPatentWatch.com
2. Clinical Infectious Diseases
3. Journal of Antimicrobial Chemotherapy
4. Antimicrobial Agents and Chemotherapy
5. Infection Control and Hospital Epidemiology
6. Journal of Clinical Microbiology